Ginkgo Bioworks Holdings Inc. (DNA)
NYSE NYSE Primary 
XMEX 
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m.
DNA Stock Alert: Ginkgo Bioworks Plunges on Plan for Reverse Stock Split
Ginkgo Bioworks (NYSE: DNA ) stock is falling on Friday after the cell programming company announced plans for a reverse split of its shares. Ginkgo Bioworks wants to enact a reverse stock split for DNA shares in the range of one-for-20 to one-for-40.
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $0.37, signifying a +0.3% move from its prior day's close.
CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
- This Version Removes the Use of 'Presentation' from the Prior-issued Headline - - Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination - STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
- Linea™ IVT Platform Delivers All The Benefits of Conventional IVT Without dsRNA Contamination - STONY BROOK, NY / ACCESSWIRE / July 29, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, will present a poster at the 4th Annual mRNA-based Therapeutics Summit taking place July 29 - 31, 2024, in Boston. The poster presents the Company's Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase - as a solution to enable mRNA producers to manufacture better mRNA faster via simplified workflows and reduced double-stranded RNA (dsRNA) contamination.
Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
- Indus Group Consumes Approximately 450 Million Pounds of Cotton Annually for the Manufacture of Apparel, Footwear, and Accessories for Global Brands and Retailers - STONY BROOK, NY / ACCESSWIRE / July 25, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the signing of a five-year license and commercialization agreement for its CertainT ® traceability platform (the "Agreement") with Indus Group ("Indus") a multinational apparel/textile manufacturing and sourcing company with a reputation for cutting-edge fabric technology and product innovation. Indus consumes approximately 450 million pounds of cotton annually.
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.30, representing a +0.6% change from its previous close.
U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year option periods entered into in May 2021. The contract supports DLA's counterfeit mitigation initiatives and product verification and testing programs specific to FSC 5962 microcircuits.
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
Ginkgo Bioworks Holdings (NYSE: DNA ), which develops platforms for cell programming, has multiple, positive potential catalysts and a rather low valuation. Moreover, the shares should benefit from investors' recent interest in buying small-cap stocks that have lost a great deal of their value.
DNA Stock: Ginkgo Bioworks Announces New Collaboration
Biotechnology specialist Ginkgo Bioworks (NYSE: DNA ) is seeing shares skyrocket today following an announcement of a potentially lucrative collaboration. Specifically, Ginkgo will partner with Syngenta, which is billed as a “leader in agricultural innovation.
Down 81% in 2024, Is Ginkgo Bioworks Stock Still a Buy?
Ginkgo Bioworks is scaling down its workforce and operating footprint. It's also aiming to restrict the scope of the services it offers.
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $0.32, representing a -1.51% change from its previous close.
